ArticlePloS one2021

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.

Shelby L Sloan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.